BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8230415)

  • 1. Increased spacing between Sp1 and TATAA renders human immunodeficiency virus type 1 replication defective: implication for Tat function.
    Huang LM; Jeang KT
    J Virol; 1993 Dec; 67(12):6937-44. PubMed ID: 8230415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.
    Chang LJ; McNulty E; Martin M
    J Virol; 1993 Feb; 67(2):743-52. PubMed ID: 8419644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat.
    Berkhout B; Jeang KT
    J Virol; 1992 Jan; 66(1):139-49. PubMed ID: 1727476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.
    Kashanchi F; Shibata R; Ross EK; Brady JN; Martin MA
    J Virol; 1994 May; 68(5):3298-307. PubMed ID: 8151790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of limiting steps for efficient trans-activation of HIV-1 promoter by Tat in Saccharomyces cerevisiae.
    Daviet L; Bois F; Battisti PL; Gatignol A
    J Biol Chem; 1998 Oct; 273(43):28219-28. PubMed ID: 9774443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.
    Kamine J; Subramanian T; Chinnadurai G
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8510-4. PubMed ID: 1924310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators.
    Kamine J; Subramanian T; Chinnadurai G
    J Virol; 1993 Nov; 67(11):6828-34. PubMed ID: 8411386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.
    Lu X; Welsh TM; Peterlin BM
    J Virol; 1993 Apr; 67(4):1752-60. PubMed ID: 8445708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat.
    Harrich D; Garcia J; Wu F; Mitsuyasu R; Gonazalez J; Gaynor R
    J Virol; 1989 Jun; 63(6):2585-91. PubMed ID: 2657100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1.
    Kamine J; Chinnadurai G
    J Virol; 1992 Jun; 66(6):3932-6. PubMed ID: 1583736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.
    Suñé C; García-Blanco MA
    J Virol; 1995 Oct; 69(10):6572-6. PubMed ID: 7666561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.
    Jeang KT; Chun R; Lin NH; Gatignol A; Glabe CG; Fan H
    J Virol; 1993 Oct; 67(10):6224-33. PubMed ID: 7690421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1.
    Kim YS; Kim JM; Jung DL; Kang JE; Lee S; Kim JS; Seol W; Shin HC; Kwon HS; Van Lint C; Hernandez N; Hur MW
    J Biol Chem; 2005 Jun; 280(22):21545-52. PubMed ID: 15743774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.
    Rittner K; Churcher MJ; Gait MJ; Karn J
    J Mol Biol; 1995 May; 248(3):562-80. PubMed ID: 7752225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the TATA motif to Tat-mediated transcriptional activation of human immunodeficiency virus gene expression.
    Olsen HS; Rosen CA
    J Virol; 1992 Sep; 66(9):5594-7. PubMed ID: 1501293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat.
    Wang L; Mukherjee S; Jia F; Narayan O; Zhao LJ
    J Biol Chem; 1995 Oct; 270(43):25564-9. PubMed ID: 7592727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
    McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
    Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.